Market Overview

Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest EPS Estimates For The Next Quarter

Related BIIB
25 Stocks Which Rallied Four Days, Then Sold Off On Friday
AC Immune Is An Alzheimer's Pure Play With A Lot On The Line
Notable earnings before Wednesday's open (Seeking Alpha)
Related AMGN
Amgen, Target, Universal Display: Fast Money Picks For October 12
Following Kite Pharma's Positive Top-Line Data, Focus Turns To Commercial Outlook
The Vetr community has upgraded $AMGN to 4.5-Stars. (Vetr)

Below are the top biotechnology stocks on the NASDAQ in terms of earnings estimate for the next quarter.

Biogen Idec (NASDAQ: BIIB) is estimated to post earnings of $2.07 per share in the September quarter. Biogen Idec's trailing-twelve-month revenue is $5.64 billion.

Amgen (NASDAQ: AMGN) is expected to earn $1.80 per share in the September quarter. Amgen's trailing-twelve-month operating margin is 34.08%.

Jazz Pharmaceuticals Public Limited Company (NASDAQ: JAZZ) is likely to earn $1.46 per share in the June quarter. Jazz Pharmaceuticals had $387.20 million in total cash for the latest quarter.

Celgene (NASDAQ: CELG) may earn $1.45 per share in the September quarter. Celgene's PEG ratio is 0.94.

Posted-In: Biotechnology Industry Highest EPS Estimates NASDAQ StocksTrading Ideas


Related Articles (AMGN + BIIB)

View Comments and Join the Discussion!